Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

12/6/24 4:26:03 PM ET

Real Estate

Get the next $OPRX alert in real time by email

SC 13G/A 1 OptimizeRx13g113024.txt OPRX 13G/A THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* OptimizeRx Corporation (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 6840IU204 (CUSIP Number) November 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person?s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 6840IU204 (1) Names of Reporting Persons. I.R.S. Identification Nos. of Above Persons (entities only): AWM Investment Company, Inc. (2) Check the Appropriate Box if a Member of a Group (See Instructions) (a)___ b)___ (3) SEC Use Only (4) Citizenship or Place of Organization: Delaware, United States Number of Shares Beneficially Owned by Each Reporting Person With (5) Sole Voting Power: 878,485** (6) Shared Voting Power: 0** (7) Sole Dispositive Power: 878,485** (8) Shared Dispositive Power: 0** (9) Aggregate Amount Beneficially Owned by Each Reporting Person: 878,485** (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions): (11) Percent of Class Represented by Amount in Row (9): 4.8%** (12) Type of Reporting Person (See Instructions): IA **AWM Investment Company, Inc., a Delaware corporation (AWM), is the investment adviser to Special Situations Cayman Fund, L.P. (CAYMAN), Special Situations Fund III QP, L.P. (SSFQP) and Special Situations Private Equity Fund, L.P. (SSPE). (CAYMAN, SSFQP and SSPE will hereafter be referred to as the Funds). As the investment adviser to the Funds, AWM holds sole voting and investment power over 142,727 shares of Common Stock of the Issuer (the Shares) held by CAYMAN, 483,383 Shares held by SSFQP and 252,375 Shares held by SSPE. See Items 2 and 4 of this Schedule for additional information. Item 1(a). Name Of Issuer: OptimizeRx Corporation Item 1(b). Address of Issuer?s Principal Executive Offices: 260 Charles Street ? Suite 302 Waltham, Massachusetts 02453 Item 2(a). Name of Person Filing: The person filing this report is AWM Investment Company, Inc., a Delaware corporation (AWM), which is the investment adviser to Special Situations Cayman Fund, L.P., a Cayman Islands Limited Partnership (CAYMAN), Special Situations Fund III QP, L.P., a Delaware limited partnership (SSFQP) and Special Situations Private Equity Fund, L.P., a Delaware limited partnership (SSPE), (CAYMAN, SSFQP and SSPE, will hereafter be referred to as the Funds). The principal business of each Fund is to invest in equity and equity-related securities and other securities of any kind or nature. David M. Greenhouse (Greenhouse) and Adam C. Stettner (Stettner) are members of: SSCayman, L.L.C., a Delaware limited liability company (SSCAY), the general partner of CAYMAN; MGP Advisers Limited Partnership, a Delaware limited partnership (MGP), the general partner of SSFQP and MG Advisers, L.L.C., a New York limited liability company (MG), the general partner of SSPE. Greenhouse and Stettner are also controlling principals of AWM. Item 2(b). Address of Principal Business Office or, if None, Residence: The principal business address for AWM is c/o Special Situations Funds, 527 Madison Avenue, Suite 2600, New York, NY 10022. Item 2(c). Citizenship: AWM is a Delaware Corporation. Item 2(d). Title of Class of Securities: Common Stock, Par Value $0.001 Item 2(e). CUSIP No.: 6840IU204 Item 3. If This Statement Is Filed Pursuant to ??240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a: Not Applicable. Item 4. Ownership (a) Amount Beneficially Owned: 878,485** (b) Percent of Class: 4.8%** (c) Number of Shares as to which the person has: (i) sole power to vote or to direct the vote: 878,485** (ii) shared power to vote or to direct the vote: 0** (iii) sole power to dispose or to direct the disposition of: 878,485** (iv) shared power to dispose or to direct the disposition of: 0** ______________________________________________________________________ ** AWM is the investment adviser to each of the Funds. As the investment adviser to the Funds, AWM holds sole voting and investment power over 142,727 shares of Common Stock of the Issuer (the Shares) held by CAYMAN, 483,383 Shares held by SSFQP and 252,375 Shares held by SSPE. Greenhouse and Stettner are members of: SSCAY, the general partner of CAYMAN; MGP, the general partner of SSFQP; and MG, the general partner of SSPE. Greenhouse and Stettner are also controlling principals of AWM. Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. _X__ Item 6. Ownership of More Than Five Percent on Behalf of Another Person Not Applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person Not Applicable. Item 8. Identification and Classification of Members of the Group Not Applicable. Item 9. Notice of Dissolution of Group Not Applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: December 6, 2024 AWM INVESTMENT COMPANY, INC. By: /s/ Adam Stettner___ Name: Adam Stettner Title: Executive Vice President Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001) -1-

Get the next $OPRX alert in real time by email

Recent Analyst Ratings for

$OPRX

Date	Price Target	Rating	Analyst
1/8/2025	$7.00 → $6.00	Outperform → Sector Perform	RBC Capital Mkts
12/20/2024	$5.50	Equal-Weight	Stephens
7/25/2024	$18.50	Buy	B. Riley Securities
4/4/2024	$15.00	Mkt Outperform	JMP Securities
1/3/2024	$15.00	Equal Weight	Barclays
2/2/2023	$30.00	Buy	B. Riley Securities
11/1/2022	$19.00	Buy	Stifel
7/15/2022	$38.00	Outperform	SVB Leerink

More analyst ratings

Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

12/6/24 4:26:03 PM ET

$OPRX

Real Estate

Get the next $OPRX alert in real time by email

Recent Analyst Ratings for

$OPRX

Date	Price Target	Rating	Analyst
1/8/2025	$7.00 → $6.00	Outperform → Sector Perform	RBC Capital Mkts
12/20/2024	$5.50	Equal-Weight	Stephens
7/25/2024	$18.50	Buy	B. Riley Securities
4/4/2024	$15.00	Mkt Outperform	JMP Securities
1/3/2024	$15.00	Equal Weight	Barclays
2/2/2023	$30.00	Buy	B. Riley Securities
11/1/2022	$19.00	Buy	Stifel
7/15/2022	$38.00	Outperform	SVB Leerink

More analyst ratings

Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$OPRX

Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$OPRX

$OPRX
SEC Filings

SEC Form 144 filed by OptimizeRx Corporation

OptimizeRx Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by OptimizeRx Corporation

$OPRX
Press Releases

OptimizeRx to Participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference

OptimizeRx Partners with Lamar Advertising to Reach Clinically Relevant Audiences Through Out-of-Home Healthcare Advertising

OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth

$OPRX
Insider Trading

Director Spangler Patrick D sold $194,489 worth of shares (11,120 units at $17.49), decreasing direct ownership by 20% to 44,215 units (SEC Form 4)

Chief Executive Officer Silvestro Stephen L was granted 15,625 shares, increasing direct ownership by 9% to 183,887 units (SEC Form 4)

Chief Legal & Admin Officer Odence-Ford Marion was granted 15,625 shares, increasing direct ownership by 22% to 85,901 units (SEC Form 4)

$OPRX
Insider Purchases

Director Lang James Paul bought $2,443,761 worth of shares (321,408 units at $7.60), increasing direct ownership by 472% to 389,452 units (SEC Form 4)

CEO Febbo William J bought $100,220 worth of shares (20,000 units at $5.01), increasing direct ownership by 3% to 601,253 units (SEC Form 4)

$OPRX
Analyst Ratings

OptimizeRx downgraded by RBC Capital Mkts with a new price target

Stephens initiated coverage on OptimizeRx with a new price target

B. Riley Securities resumed coverage on OptimizeRx with a new price target

$OPRX
Leadership Updates

OptimizeRx Partners with Lamar Advertising to Reach Clinically Relevant Audiences Through Out-of-Home Healthcare Advertising

OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth

Paynela Appoints Healthcare Technology Veteran William Febbo to Board of Directors

$OPRX
Financials

OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

$OPRX
Large Ownership Changes